On October 3, 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, reported that an abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2023, taking place in San Diego, California and virtually from 1 to 5 November 2023 (Press release, Immutep, OCT 3, 2023, View Source [SID1234635573]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Title: Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab
Abstract Number: 595
Date and Time: Friday, 3 November, 9:00 AM-7:00 PM PT
Location: Exhibit Halls A and B1, San Diego Convention Centre
The abstract will be available on the SITC (Free SITC Whitepaper) website as of October 31, 2023, and the poster will be available on the Posters & Publications section of Immutep’s website following the presentation.